Naringenin as a potential immunomodulator in therapeutics

被引:197
作者
Zeng, Wenfeng [1 ]
Jin, Lingtao [2 ]
Zhang, Fayun [1 ]
Zhang, Chunling [1 ]
Liang, Wei [1 ]
机构
[1] Chinese Acad Sci, Inst Biophys, Prot & Peptide Pharmaceut Lab, Beijing, Peoples R China
[2] Emory Univ, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA
关键词
Naringenin; Citrus flavonoids; Inflammation; Apigenin; NF-KAPPA-B; INDUCED GASTRIC CARCINOGENESIS; CELL-CYCLE ARREST; CANCER-CELLS; DOWN-REGULATION; ACUTE-INFLAMMATION; INDUCED APOPTOSIS; INDUCE APOPTOSIS; LUNG METASTASIS; IN-VITRO;
D O I
10.1016/j.phrs.2018.08.002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Naringenin, a citrus flavonoid that possesses various biological activities, has emerged as a potential therapeutic agent for the management of a variety of diseases. Studies using cell culture system have shown that naringenin can inhibit inflammatory response in diverse cell types. Moreover, research using various animal models has further demonstrated therapeutic potentials of naringenin in the treatment of several inflammation-related disorders, such as sepsis, fulminant hepatitis, fibrosis and cancer. The mechanism of action of naringenin is not completely understood but recent mechanistic studies revealed that naringenin suppresses inflammatory cytokine production through both transcriptional and post-transcriptional mechanisms. Surprisingly, naringenin not only inhibits cytokine mRNA expression but also promotes lysosome-dependent cytokine protein degradation. This unique property of naringenin stands in sharp contrast with some widely-studied natural products such as apigenin and curcumin, which regulate cytokine production essentially at the transcriptional level. Therefore, naringenin may provide modality for the development of novel anti-inflammatory agent. This review article summarizes our recent studies in understanding how naringenin acts in cells and animal models. Particularly, we will discuss the anti-inflammatory activities of naringenin in various disease context and its potential use, as an immunomodulator, in the treatment of inflammatory related disease.
引用
收藏
页码:122 / 126
页数:5
相关论文
共 98 条
[61]   Dexamethasone inhibits IL-12p40 production in lipopolysaccharide-stimulated human monocytic cells by down-regulating the activity of c-jun N-terminal kinase, the activation protein-1, and NF-κB transcription factors [J].
Ma, W ;
Gee, K ;
Lim, W ;
Chambers, K ;
Angel, JB ;
Kumar, A .
JOURNAL OF IMMUNOLOGY, 2004, 172 (01) :318-330
[62]   Subcompartments of the macrophage recycling endosome direct the differential secretion of IL-6 and TNFα [J].
Manderson, Anthony P. ;
Kay, Jason G. ;
Hammond, Luke A. ;
Brown, Darren L. ;
Stow, Jennifer L. .
JOURNAL OF CELL BIOLOGY, 2007, 178 (01) :57-69
[63]   INHIBITION OF LUNG METASTASIS IN MICE INDUCED BY B16F10 MELANOMA-CELLS BY POLYPHENOLIC COMPOUNDS [J].
MENON, LG ;
KUTTAN, R ;
KUTTAN, G .
CANCER LETTERS, 1995, 95 (1-2) :221-225
[64]   Citrus Flavonoids as Regulators of Lipoprotein Metabolism and Atherosclerosis [J].
Mulvihill, Erin E. ;
Burke, Amy C. ;
Huff, Murray W. .
ANNUAL REVIEW OF NUTRITION, VOL 36, 2016, 36 :275-299
[65]   Naringenin Decreases Progression of Atherosclerosis by Improving Dyslipidemia in High-Fat-Fed Low-Density Lipoprotein Receptor-Null Mice [J].
Mulvihill, Erin E. ;
Assini, Julia M. ;
Sutherland, Brian G. ;
DiMattia, Alessandra S. ;
Khami, Maryam ;
Koppes, Julie B. ;
Sawyez, Cynthia G. ;
Whitman, Stewart C. ;
Huff, Murray W. .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2010, 30 (04) :742-U224
[66]   Naringenin Prevents Dyslipidemia, Apolipoprotein B Overproduction, and Hyperinsulinemia in LDL Receptor-Null Mice With Diet-Induced Insulin Resistance [J].
Mulvihill, Erin E. ;
Allister, Emma M. ;
Sutherland, Brian G. ;
Telford, Dawn E. ;
Sawyez, Cynthia G. ;
Edwards, Jane Y. ;
Markle, Janet M. ;
Hegele, Robert A. ;
Huff, Murray W. .
DIABETES, 2009, 58 (10) :2198-2210
[67]   A role for the phagosome in cytokine secretion [J].
Murray, RZ ;
Kay, JG ;
Sangermani, DG ;
Stow, JL .
SCIENCE, 2005, 310 (5753) :1492-1495
[68]   Apolipoprotein B-dependent hepatitis C virus secretion is inhibited by the grapefruit flavonoid naringenin [J].
Nahmias, Yaakov ;
Goldwasser, Jonathan ;
Casali, Monica ;
van Poll, Daan ;
Wakita, Takaji ;
Chung, Raymond T. ;
Yarmush, Martin L. .
HEPATOLOGY, 2008, 47 (05) :1437-1445
[69]   Naringin attenuates EGF-induced MUC5AC secretion in A549 cells by suppressing the cooperative activities of MAPKs-AP-1 and IKKs-IκB-NF-κB signaling pathways [J].
Nie, Yi-chu ;
Wu, Hao ;
Li, Pei-bo ;
Xie, Li-ming ;
Luo, Yu-long ;
Shen, Jian-gang ;
Su, Wei-wei .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2012, 690 (1-3) :207-213
[70]   Metformin-like antidiabetic, cardio-protective and non-glycemic effects of naringenin: Molecular and pharmacological insights [J].
Nyane, Ntsoaki Annah ;
Tlaila, Thabiso Bethwel ;
Malefane, Tanki Gabriel ;
Ndwandwe, Dudu Edith ;
Owira, Peter Mark Oroma .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2017, 803 :103-111